Targeted nanoparticles

Abstract

The invention in the various aspects provides nanogel compositions that are safe for topical, local, and/or systemic delivery, and which can be targeted to select tissues or cells, including pathogens. In some embodiments, conjugation of antibiotics to the nanogel surface, and in particular antibiotics that disrupt outer membranes of Gram negative bacteria or antibiotics that inhibit cell wall synthesis, provide for highly effective targeting and killing of bacterial pathogens, including drug-resistant bacteria.

1 . A hydrogel composition, comprising:
 a population of polymeric nanoparticles having conjugated to their surface polymyxin B and/or Vancomycin.   
     
     
         2 . The hydrogel composition of  claim 1 , wherein the nanoparticles have polymyxin B conjugated to their surface. 
     
     
         3 . The hydrogel composition of  claim 1 , wherein the nanoparticles have vancomycin conjugated to their surface. 
     
     
         4 . The hydrogel composition of  claim 1 , wherein the nanoparticles have polymyxin B and vancomycin conjugated to their surface. 
     
     
         5 . The hydrogel composition of  claim 1 , wherein the nanoparticles comprise cross-linked copolymers. 
     
     
         6 . The hydrogel composition of  claim 5 , wherein at least one co-polymer is a polysaccharide, which is either linear, cyclic or branched. 
     
     
         7 . The hydrogel composition of  claim 6 , wherein the polysaccharide is a glucan. 
     
     
         8 . The hydrogel composition of  claim 6 , wherein the polysaccharide is at least one of dextran, chitosan, and cyclodextran. 
     
     
         9 . The hydrogel composition of  claim 5 , wherein at least one co-polymer is selected from polyvinyl alcohol, acrylate, and polyacrylate. 
     
     
         10 .- 40 . (canceled) 
     
     
         41 . A hydrogel preparation comprising nanoparticles of dextran cross-linked with poloxamer, and having surface conjugated antibiotic that disrupts outer membrane of gram negative bacteria, or inhibits cell wall synthesis of gram positive or gram negative bacteria. 
     
     
         42 . The hydrogel composition of  claim 41 , wherein the nanoparticles have polymyxin B conjugated to their surface. 
     
     
         43 . The hydrogel composition of  claim 41 , wherein the nanoparticles have a glycopeptide antibiotic conjugated to their surface. 
     
     
         44 . The hydrogel composition of  claim 43 , wherein the glycopeptide antibiotic is vancomycin or teicoplanin or lipoglycopeptide derivatives, telavancin, dalbavancin, and oritavancin. 
     
     
         45 . The hydrogel composition of  claim 41 , wherein the nanoparticles have a beta lactam antibiotic conjugated to their surface. 
     
     
         46 . The hydrogel composition of  claim 45 , wherein beta lactam is penicillin or cephalosporin. 
     
     
         47 . The hydrogel composition of  claim 41 , wherein the nanoparticles have polymyxin B and vancomycin conjugated to their surface. 
     
     
         48 . The hydrogel composition of  claim 41 , wherein the dextran and poloxamer co-polymers are cross-linked by radical polymerization, emulsion polymerization, UV initiated cross-linking, or e-beam curing. 
     
     
         49 .- 96 . (canceled) 
     
     
         97 . The hydrogel composition of  claim 1 , further comprising an encapsulated therapeutic or diagnostic agent, wherein the therapeutic or diagnostic agent is a glucocorticoid, monoclonal antibody, polynucleotide, an enzyme, hormone, anti-inflammatory agent, cytotoxic agent, LpxC inhibitor, and pharmaceutical formulations including the compounds, for inhibiting UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase, siRNA, or radiosiotope. 
     
     
         98 . The hydrogel composition of  claim 97 , wherein the therapeutic agent is budesonide, naproxen, aspirin, ketoprofen, ibuprofren, diclofenac, or indomethacin. 
     
     
         99 . The hydrogel composition of  claim 97 , wherein the diagnostic agent is a fluorescently labelled agent or a radio-labelled biomarker. 
     
     
         100 .- 109 . (canceled)